Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;6(Suppl 3):e009918.
doi: 10.1136/bmjgh-2022-009918.

Why falsified medicines reach patients: an analysis of political and economic factors in Romania

Affiliations
Review

Why falsified medicines reach patients: an analysis of political and economic factors in Romania

Adina-Loredana Nistor et al. BMJ Glob Health. 2023 Feb.

Abstract

Introduction: To protect patients against falsified medicines, countries around the world implement stringent regulations. Despite efforts to protect supply chains in the European Union (EU), authorities continue to find falsified medicine. We studied how in Romania, one of the poorest EU countries, political and economic factors influence the risk of patients being exposed to falsified medicines.

Methods: For this case study, we reviewed 131 documents and interviewed 22 purposively selected key informants.

Results: In Romania, several politically and economically motivated policies have led to persistent medicine shortages. Following the 2007 accession to the EU, fierce competition led to a decline in domestic medicine production. Soon after, the government introduced a tax on reimbursed medicines to support the national health budget. Prior to the 2015 elections, medicine prices were abruptly lowered to provide voters with the cheapest medicine in Europe. The low prices incentivised traders to buy medicines in Romania and sell them elsewhere in the EU. The high taxes and low prices led manufacturers to withdraw medicines from the market and impose product quotas to limit parallel trading. The accumulated effect of these market responses translated into persistent shortages of essential medicine, which have pushed patients and health professionals to unregulated markets with a high risk of exposure to falsified medicine.

Conclusion: Strategies against falsified medicine with a narrow focus on safeguarding quality in the regulated supply are insufficient. To protect patients, governments must also ensure that patients have access to affordable medicines, as shortages provide an opportunity for those selling fake products.

Keywords: Health policy; Health services research; Health systems; Pharmacology; Public Health.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Timeline of key events. GDP, good distribution practice; GMP, good manufacturing practice.

References

    1. World Health Organization . Who global surveillance and monitoring system for substandard and falsified medical products. Geneva, 2017. http://www.who.int/medicines/regulation/ssffc/publications/GSMS_Report.pdf
    1. European Commission . Directive 2011/62/EU of the European Parliament and of the Council, of 8 June 2011 amending Directive 2001/83/EC on the community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products, 2011. Available: /health/human-use/falsified_medicines_en [Accessed 21 Jan 2018].
    1. Nayyar GML, Breman JG, Herrington JE. The global pandemic of falsified medicines: laboratory and field innovations and policy perspectives. Am J Trop Med Hyg 2015;92:2–7. 10.4269/ajtmh.15-0221 - DOI - PMC - PubMed
    1. Buckley GJB, Gostin LO. Countering the problem of falsified and substandard drugs: committee on understanding the global public health implications of substandard, falsified, and counterfeit medical products. Washington, D.C: National Academies Press, Institute of Medicine of the National Academies, 2013. - PubMed
    1. Fadlallah R, El-Jardali F, Annan F, et al. . Strategies and Systems-Level interventions to combat or prevent drug Counterfeiting: a systematic review of evidence beyond effectiveness. Pharmaceut Med 2016;30:263–76. 10.1007/s40290-016-0156-4 - DOI - PMC - PubMed

Publication types

Substances